[lymphoma and myeloma] phase iii trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
November 13th, 2008 by 
admin Conclusion
Consolidation of prototypal referral with 90Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly trenchant with no unheralded toxicities, prolonging PFS by 2 eld and resulting in broad PR-to-CR transmutation rates disregarding of identify of first-line stimulation treatment. (Source: Journal of Clinical Oncology)
Tags: ATM
Posted in Cancer | 